Janssen Research & Development, a J&J unit, has established a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Co. are the first two companies to join Janssen in this effort. It is anticipated that the Investigator Databank will be operational by the end of the year. It will be hosted by DrugDev.org, an independent, third party with expertise in clinical trial IT and investigator community management.
The new Investigator Databank will serve as a repository housing key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, with the goal of allowing participating pharma companies to reduce time-consuming and redundant administrative work involved in identifying clinical trial sites.
“The current clinical trial environment is inefficient, costly and unsustainable. The Investigator Databank can help expedite the process to achieve our most important goal — to deliver high-quality, effective novel medicines to the patients who are waiting for them,” said Andreas Koester, MD, Ph.D., head, Clinical Trial Innovation/External Alliances, Janssen R&D. “We are enthusiastic about working with other industry leaders to collectively apply our expertise, capabilities and shared passion for advancing science and improving lives.”